metaPreg - Thiouracil, propylthiouracil, benzylthiouracil during pregnancy

Thiouracil, propylthiouracil, benzylthiouracil

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	1.01 [0.83, 1.22]	31%	11 studies	249,671	13,231	not evaluable	unclear
Major congenital malformations	0.70 [0.46, 1.07]	0%	6 studies	180	1,640	not evaluable	unclear
Genital anomalies	1.22 [0.96, 1.54]	0%	3 studies	25,811	11,037	not evaluable	critical
Limb defects	1.20 [1.05, 1.37]	0%	3 studies	74,706	11,037	not evaluable	critical
Respiratory system anomalies	1.22 [0.76, 1.96]	33%	3 studies	16,007	11,037	not evaluable	critical
Urinary malformations	1.63 [1.01, 2.62]	38%	3 studies	17,696	11,037	not evaluable	critical
Eye defects	0.44 [0.06, 3.31]	0%	2 studies	2,484	1,107	not evaluable	critical
Congenital heart defects	1.05 [0.84, 1.31]	17%	3 studies	77,568	11,037	not evaluable	critical
Severe congenital heart defect	1.20 [0.06, 22.67]	70%	2 studies	739	1,446	not evaluable	unclear
Abdominal wall defects	1.19 [0.15, 9.65]	0%	2 studies	926	1,107	not evaluable	critical
Ano-rectal atresia and stenosis	1.62 [0.19, 14.09]	62%	3 studies	1,056	1,954	not evaluable	unclear
Carbimazole embryopathy	1.60 [0.92, 2.79]	0%	3 studies	2,243	11,423	not evaluable	unclear
Digestive system anomalies	1.47 [0.59, 3.67]	40%	2 studies	12,045	10,148	not evaluable	critical
Nervous system anomalies	1.09 [0.72, 1.65]	0%	2 studies	5,868	10,148	not evaluable	critical
Omphalocele	0.79 [0.19, 3.22]	0%	3 studies	159	1,987	not evaluable	unclear
Syndromes and chromosomal abnormalities	0.84 [0.33, 2.12]	0%	2 studies	5,547	1,107	not evaluable	critical
Atresia of bile ducts	0.36 [0.04, 3.50]	0%	2 studies	2	1,940	not evaluable	unclear
Cardiac septal defects	-	-	0 study
Congenital hydronephrosis	2.85 [0.67, 12.10]	0%	2 studies	9	1,940	not evaluable	unclear
Hypospadias	2.38 [0.35, 16.30]	0%	2 studies	4	1,940	not evaluable	unclear
Oro-facial clefts	0.98 [0.56, 1.70]	0%	2 studies	3,460	10,471	not evaluable	unclear
Ventricular septal defect	0.89 [0.42, 1.88]	0%	2 studies	28	1,940	not evaluable	unclear
Aortic valve atresia/stenosis	3.29 [0.12, 89.46]	70%	2 studies	494	1,412	not evaluable	critical
Craniosynostosis	1.19 [0.30, 4.68]	0%	2 studies	1,535	1,411	not evaluable	critical
Ear malformations	35.97 [1.72, 751.88]	-	1 study	2	218	not evaluable	critical
Pulmonary valve stenosis	0.77 [0.15, 4.01]	0%	2 studies	1,517	552	not evaluable	unclear
Situs inversus	15.05 [1.80, 126.08]	0%	2 studies	27	1,446	not evaluable	unclear
Coarctation of aorta	7.97 [1.64, 38.62]	-	1 study	1,137	14	not evaluable	critical
27 non statistically significant endpoints reported in only one study
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
Preterm (< 37 weeks)	1.03 [0.73, 1.46]	5%	5 studies	291	832	not evaluable	unclear
Low birth weight (< 2500g)	1.41 [1.01, 1.97]	0%	2 studies	185	637	not evaluable	unclear
1 non statistically significant endpoints reported in only one study
Maternal consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
Caesarean	1.09 [0.31, 3.78]	69%	2 studies	97	95	not evaluable	critical
3 non statistically significant endpoints reported in only one study
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
Goiter	1.35 [0.37, 4.94]	0%	5 studies	8	167	not evaluable	unclear
Hypothyroidism (fetal/neonatal)	0.97 [0.18, 5.39]	0%	4 studies	3	180	not evaluable	unclear
Hearing loss / Auditory deficit	0.43 [0.06, 3.05]	0%	2 studies	4	1,940	not evaluable	unclear
Hyperthyroidism / Thyrotoxicosis (fetal/neonatal)	0.87 [0.12, 6.53]	0%	3 studies	2	81	not evaluable	unclear
Neonatal hyperthyrotropinemia	3.82 [0.36, 40.91]	57%	2 studies	15	86	not evaluable	unclear
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
Elective termination of pregnancy	1.32 [0.72, 2.42]	0%	3 studies	67	1,745	not evaluable	unclear
Early intrauterine death (< 22 weeks)	1.24 [0.62, 2.47]	58%	3 studies	394	1,745	not evaluable	unclear
Intrauterine deaths (as a whole or unspecified)	1.23 [0.51, 2.93]	0%	3 studies	25	102	not evaluable	unclear
Perinatal death	2.00 [0.17, 23.33]	59%	2 studies	19	1,630	not evaluable	critical
Late intrauterine deaths (> 22 weeks)	0.20 [0.01, 6.47]	74%	2 studies	9	167	not evaluable	unclear
Ectopic pregnancy	-	-	0 study